HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development.

AbstractCONTEXT:
Delirium is a highly prevalent complication in patients in palliative care settings, especially in the end-of-life context.
OBJECTIVES:
To review the current evidence base for treating episodes of delirium in palliative care settings and propose a framework for future development.
METHODS:
We combined multidisciplinary input from delirium researchers and other purposely selected stakeholders at an international delirium study planning meeting. This was supplemented by a literature search of multiple databases and relevant reference lists to identify studies regarding therapeutic interventions for delirium.
RESULTS:
The context of delirium management in palliative care is highly variable. The standard management of a delirium episode includes the investigation of precipitating and aggravating factors followed by symptomatic treatment with drug therapy. However, the intensity of this management depends on illness trajectory and goals of care in addition to the local availability of both investigative modalities and therapeutic interventions. Pharmacologically, haloperidol remains the practice standard by consensus for symptomatic control. Dosing schedules are derived from expert opinion and various clinical practice guidelines as evidence-based data from palliative care settings are limited. The commonly used pharmacologic interventions for delirium in this population warrant evaluation in clinical trials to examine dosing and titration regimens, different routes of administration, and safety and efficacy compared with placebo.
CONCLUSION:
Delirium treatment is multidimensional and includes the identification of precipitating and aggravating factors. For symptomatic management, haloperidol remains the practice standard. Further high-quality collaborative research investigating the appropriate treatment of this complex syndrome is needed.
AuthorsShirley H Bush, Salmaan Kanji, José L Pereira, Daniel H J Davis, David C Currow, David Meagher, Kiran Rabheru, David Wright, Eduardo Bruera, Michael Hartwick, Pierre R Gagnon, Bruno Gagnon, William Breitbart, Laura Regnier, Peter G Lawlor
JournalJournal of pain and symptom management (J Pain Symptom Manage) Vol. 48 Issue 2 Pg. 231-248 (Aug 2014) ISSN: 1873-6513 [Electronic] United States
PMID24480529 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2014 American Academy of Hospice and Palliative Medicine. All rights reserved.
Chemical References
  • Antipsychotic Agents
  • Haloperidol
Topics
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Delirium (therapy)
  • Haloperidol (adverse effects, therapeutic use)
  • Humans
  • Palliative Care (methods)
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: